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Exosomes, nanosized membrane vesicles secreted by cardiac progenitor cells
(Exo-CPC), inhibit cardiomyocyte apoptosis under stress conditions, promote
angiogenesis in vitro, and prevent the early decline in cardiac function after myocardial
infarction in vivo in preclinical rat models. The recognition of exosome-mediated
effects has moved attempts at developing cell-free approaches for cardiac repair.
Such approaches offer major advantages including the fact that exosomes can
be stored as ready-to-use agents and delivered to patients with acute coronary
syndromes. The aim of the present work was the development of a good manufacturing
practice (GMP)-grade method for the large-scale preparation of Exo-CPC as a
medicinal product, for a future clinical translation. A GMP-compliant manufacturing
method was set up, based on large-scale cell culture in xeno-free conditions,
collection of up to 8 l of exosome-containing conditioned medium and isolation
of Exo-CPC through tangential flow filtration. Quality control tests were developed
and carried out to evaluate safety, identity, and potency of both cardiac progenitor
cells (CPC) as cell source and Exo-CPC as final product (GMP-Exo-CPC). CPC,
cultured in xeno-free conditions, showed a lower doubling-time than observed in
research-grade condition, while producing exosomes with similar features. Cells
showed the typical phenotype of mesenchymal progenitor cells (CD73/CD90/CD105
positive, CD14/CD20/CD34/CD45/HLA-DR negative), and expressed mesodermal
(TBX5/TBX18) and cardiac-specific (GATA4/MESP1) transcription factors. Purified
GMP-Exo-CPC showed the typical nanoparticle tracking analysis profile and expressed
main exosome markers (CD9/CD63/CD81/TSG101). The GMP manufacturing method
guaranteed high exosome yield (>1013 particles) and consistent removal (≥97%) of
contaminating proteins. The resulting GMP-Exo-CPC were tested for safety, purity,
identity, and potency in vitro, showing functional anti-apoptotic and pro-angiogenic
activity. The therapeutic efficacy was validated in vivo in rats, where GMP-Exo-CPC
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ameliorated heart function after myocardial infarction. Our standardized production
method and testing strategy for large-scale manufacturing of GMP-Exo-CPC open new
perspectives for reliable human therapeutic applications for acute myocardial infarction
syndrome and can be easily applied to other cell sources for different therapeutic areas.
Keywords: exosomes, cardiac progenitor cells, good manufacturing practices, large-scale production, quality
control
INTRODUCTION
Exosomes are EV of endosomal origin, with a diameter of
30–150 nm, involved in intercellular communication processes.
They are secreted by virtually all cell types and express
characteristic exosomal markers, such as CD9, CD63, CD81, Alix,
and TSG101, as well as markers typical of the cells from which
they originate. Cell origin is also a determinant for the microRNA
content (Thery et al., 2006; Cervio et al., 2015; Kowal et al., 2016;
Barile et al., 2017b; Sluijter et al., 2018; Van Niel et al., 2018).
Exo are currently the focus of various studies aimed at
clarifying their role, mechanisms of action, and potential
diagnostic and therapeutic applications (Lener et al., 2015; Barile
and Vassalli, 2017).
Recent evidence suggests that human CPC release EV that
phenotypically recapitulate Exo (Barile et al., 2012). Such vesicles
inhibit cardiomyocyte apoptosis and promote angiogenesis
in vitro, hence playing a fundamental role in the paracrine
effect of CPC. In vivo, in a preclinical model of AMI in
rats, CPC-derived Exo (Exo-CPC) reduce tissue damage, inhibit
cardiomyocyte apoptosis, and promote angiogenesis, improving
post-infarction cardiac function (Barile et al., 2014). Key
mediators of these effects have been identified in specific
microRNAs such as miR-132 and miR-210 (Barile et al.,
2014), as well as specific proteins such as the active form of
pregnancy-associated plasma protein-A (Barile et al., 2018).
Based on the above-described functional properties, Exo-CPC
represent a promising candidate for future clinical applications,
relying on an alternative and innovative approach in respect to
cellular therapies currently being tested in the cardiovascular
field. Compared to a cellular product, isolated Exo could have
advantages in terms of safety and ease of handling, thanks to
Abbreviations: AMI, acute myocardial infarction; ATMP, advanced therapy
medicinal products; CDC, cardiosphere-derived cells; CM, conditioned medium;
CPC, cardiac progenitor cells; CPC-I, cardiac progenitor cells grown under the
GMP grade condition I; CPC-II, cardiac progenitor cells grown under the GMP
grade condition II; CPC-R, cardiac progenitor cells grown under the research
grade condition; DMEM, Dulbecco’s Modified Eagle Medium; DPBS, Dulbecco’s
phosphate buffered saline; EPC, end of production cells; EV, extracellular vesicles;
Exo, exosomes; Exo-CPC, exosomes from cardiac progenitor cells; Exo-CPC-I,
exosomes released by CPC-I; Exo-CPC-II, exosomes released by CPC-II; Exo-
CPC-R, exosomes released by CPC-R; Exo-F, exosomes from normal human
dermal fibroblasts; FBS, fetal bovine serum; FIO, for information only; GMP,
good manufacturing practices; GMP-EXO-CPC, Exo-CPC as a medicinal product
produced according GMP regulation; LVEDV, left ventricular end diastolic volume;
LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume;
MCB, master cell bank; MI, myocardial ischemia; NTA, nanoparticle tracking
analysis; PI, propidium iodide; PPCB, post-production cell bank; P2, P4, P6, P8:
culture passage 2, 4, 6, or 8; QC, quality control; RT, room temperature; SD,
standard deviation; TEM, transmission electron microscopy; TFF, tangential flow
filtration.
their low toxicity, high stability, biocompatibility, and biological
barrier permeability (Xitong and Xiaorong, 2016). Moreover,
Exo demonstrate strong potential for immunomodulation by
inhibition of lymphocyte proliferation (Monguio-Tortajada
et al., 2017) and reduction of CD68+ infiltrating cells once
injected into heart (De Couto et al., 2017). Thus, Exo can
be conceived for both autologous and allogeneic applications.
This would be particularly useful in a context of AMI
where the allogeneic use would allow the availability of an
off-the-shelf Exo-based product, ready to be infused during
percutaneous intervention to open occluded vessel as supporting
cardioprotective therapy.
Exo from different cell types are being tested in clinical trials
in several therapeutic areas, including cancer, diabetes, wound
healing (Lener et al., 2015; Barile and Vassalli, 2017; Sluijter et al.,
2018). Phase I–II immunotherapy studies for colon rectal cancer,
melanoma and non-small cell lung cancer have already been
completed with dendritic cell-derived Exo, demonstrating safety
and feasibility of the approach; partial clinical responses were also
detected in some patients (Pitt et al., 2016).
Several methods for EV and Exo isolation have been
described, based on different specific characteristics, such
as density, size, shape, and surface markers. Differential
centrifugation/ultracentrifugation, polymer-based precipitation,
filtration, size exclusion chromatography, density-gradient
centrifugation, and magnetic bead capture are the most popular
technologies according to a recent survey (Gardiner et al., 2016).
However, there is not yet a state-of–the-art method for the
production of large-scale clinical-grade EV, a context in which
scalability, reproducibility, safety, potency, and purity of the
resulting product represent crucial issues.
In this context, the development and validation of GMP-grade
methods to produce and functionally validate Exo is essential for
a future clinical translation.
The aim of the present work was the development of
production and QC methods for the large-scale preparation of
Exo-CPC as a medicinal product, in accordance with current
GMP (GMP-Exo-CPC).
The starting point for such development were the research
grade methods used so far for CPC isolation and culture
as well as for small-scale production of Exo-CPC for pilot
preclinical experiments (Barile et al., 2014, 2018). In such
basic research context, open culture vessels (Petri dishes) and
poorly standardized, animal-derived components (FBS, gelatin,
and trypsin) have been used for CPC culture and expansion.
Exo-CPC were isolated by polymer-based precipitation or
ultracentrifugation, both hardly scalable and potentially favoring
the concomitant concentration of impurities. Moreover, both
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CPC and Exo-CPC were poorly characterized, in terms of safety
(e.g., sterility) and purity aspects (presence of process-derived
contaminants), and the applied characterization and functional
assays were unsuitable for formal validation.
The approach followed throughout the present work was
focused on overcoming these limitations: the use of open culture
vessels was avoided as much as possible, xeno-free reagents
were selected as alternatives to the animal-derived ones, and
reliable and scalable isolation methods were tested. Moreover, the
analytical methods have been revisited and optimized in order
to achieve the reproducibility and robustness required for their
application in a GMP context.
Finally, CPC and GMP-Exo-CPC were extensively checked for
identity, purity, safety, and functional activity.
MATERIALS AND METHODS
Cardiac progenitor cells and Exo-CPC production methods
are described in detail in this section. Analytical methods are
outlined here and reported in detail in Supplementary Material.
CPC Isolation and Culture
Atrial appendage explants were obtained from patients subjected
to valve repair surgery who were not carriers of concomitant
coronary artery disease (n = 9, seven males and two females; age
69± 7 years; LVEF 61± 6%).
Cardiac tissue specimens were stored in a sterile vessel
containing cardioplegic solution [Plasma-Lyte A R© solution
(Baxter Healthcare, United States) supplemented with Mannitol
(final concentration 0.3%), magnesium sulfate (0.2%), sodium
bicarbonate (0.1%), lidocaine (0.01%), and potassium chloride
(0.2%), all from Sigma-Aldrich/Merck, United States] and
transferred to labs. The tissue was processed under sterile
conditions (Class A laminar hood): after transfer to a sterile
support (Petri dish, Corning, United States) two washings were
performed with Dulbecco’s phosphate buffered saline without
calcium and magnesium (DPBS, Gibco/Thermo Fisher Scientific,
United States), then the cardiac muscle tissue was isolated from
the connective tissue and minced in small fragments (around
1 mm diameter).
Research-Grade Process
Tissue fragments were placed to adhere on gelatin (Sigma-
Aldrich/Merck, United States)-coated 10 µm Petri dishes
(Corning), in the presence of IMDM culture medium (Lonza,
Switzerland) supplemented with 20% FBS (Gibco/Thermo Fisher
Scientific), then incubated at 37◦C in 5% CO2. After few
days, CPC outgrowth was observed. At confluence, CPC were
harvested through trypsin (Sigma-Aldrich/Merck) treatment,
then seeded at 8–10 × 104 cells/cm2 in appropriate flasks and
expanded in the same culture conditions (see Table 1). The flasks
were previously coated in presence of gelatin solution 0.2% in
DPBS, incubated for 30 min at RT.
CPC expanded in these research grade conditions are
thereafter indicated as CPC-R.
Setup of GMP-Grade Process
Tissue fragments were placed in 115 cm2 tissue-culture flasks
with reclosable lids (TPP, Switzerland) in the presence of
StemMACS-MSC expansion Media kit XF (Miltenyi Biotec
GmbH, Germany) after coating with CELLstartTM CTSTM
(Gibco/Thermo Fisher Scientific) or Synthemax R© II-SC
(Corning) as adhesion substrates for “GMP grade I” and
“GMP grade II” conditions, respectively (see Table 1). For the
coating with CELLstartTM CTSTM, flasks were incubated with
the reagent diluted 1:50 in DPBS for 2 h at 37◦C. Regarding the
coating with Synthemax R© II-SC, flasks were incubated with the
reagent diluted 1:40 in sterile water for 2 h at RT.
At confluence, CPC were harvested using TrypLETM Select
Enzyme (Gibco/Thermo Fisher Scientific), then seeded at
8–10× 104 cells/cm2 and expanded in T flasks (75–150 cm2),
HYPERFlask R© (1720 cm2) or HYPERStack R©-12 (6000 cm2)
culture vessels (Corning). Thanks to their negatively charged,
highly hydrophilic CellBIND R© surface (Corning), designed to
facilitate cell attachment and spreading, HYPERFlasks and
HYPERStacks did not require any coating.
For CPC MCB and PPCB generation (see below), the
above indicated StemMACS-MSC expansion Media kit XF was
substituted by its GMP counterpart, MSC-Brew GMP Medium
(test lot kindly provided by Miltenyi Biotec GmbH).
CPC expanded in GMP grade conditions I and II are thereafter
indicated as CPC-I and CPC-II, respectively.
Conditioned Medium Preparation
Cardiac progenitor cells expanded up to culture passage 4
(P4) were washed twice with DPBS and incubated at 37◦C
with 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM)
4.5 g/l glucose without phenol red (Gibco/Thermo Fisher
Scientific, catalog number 21063-029), thereafter indicated
as production medium. After 1–2 weeks, the CM was
harvested.
TABLE 1 | Different methods for CPC isolation and culture.
GMP grade I (CPC-I) GMP grade II (CPC-II) RESEARCH grade (CPC-R)
CPC isolation Adhesion substrate CELLstartTM CTSTM Synthemax R© II-SC Gelatin
Culture medium StemMACS-MSC expansion Media kit XF IMDM 20% FBS
Dissociation enzyme TrypLETM Select Trypsin
CPC expansion Adhesion substrate CellBIND R© surface Gelatin
Culture medium StemMACS-MSC expansion Media kit XF IMDM 20% FBS
Dissociation enzyme TrypLETM Select Trypsin
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Exosome Isolation
Three different methods were used throughout this study for
Exo-CPC isolation.
Ultracentrifugation
Serial centrifugation/ultracentrifugation steps were applied, as
previously described (Barile et al., 2018). Briefly, 15 ml of CM
were centrifuged at 3000 g, 4◦C, 15 min; the supernatant was
collected, filtered (0.2 µm filter, TPP), transferred in Amicon
Ultra-15 (100 kDa cut-off, Merck Millipore, Germany) and
centrifuged at 3000 g, 4◦C, for 30 min; the concentrate was
centrifuged at 10,000 g, 4◦C, for 20 min; the supernatant was
collected, diluted to 3 ml with DPBS and ultracentrifuged at
100,000 g, 4◦C, for 120 min; the resulting pellet was suspended
in 100 µl of DPBS.
This method was exclusively used for small-scale Exo
isolation, to compare Exo derived from CPC cultured in the
different conditions reported in Table 1.
Direct Filtration
The CM was clarified by centrifugation at 3000 g, 15 min
at RT, followed by filtration (0.22 µm) in bottle filter
units (TPP). Concentration was performed by direct filtration
through Amicon Ultra-15 (100 kDa cut-off) (15 ml CM/device)
or Centricon Plus-70 (100 kDa cut-off, Merck Millipore)
(65 ml CM/device), centrifuged at 3000 g, RT, 30 min. Each
resulting concentrated sample was diluted about 1:10 with
Plasma-Lyte A R© solution and concentrated again using the same
device.
This method was applied during process scale up.
Tangential Flow Filtration (TFF)
The CM was clarified by 0.22 µm filtration through bottle filter
units or online filters (ULTA Capsule HC, KMP-HC9202HH, GE
Healthcare, United States). Concentration was performed by TFF,
using the ÄKTATM flux 6 system (GE Healthcare) equipped with
a 300 kDa cut-off hollow fiber cartridge (GE Healthcare); the
concentration was followed by diafiltration in five volumes of
Plasma-Lyte A R© solution. Process details are reported below.
This method was applied during process scale up and for the
large-scale manufacturing of GMP-Exo-CPC.
CPC Master Cell Bank and
Post-production Cell Bank
Cardiac progenitor cells were isolated and cultured according to
the “GMP grade I” method described above, using CELLstartTM
CTSTM as adhesion substrate and MSC-Brew GMP Medium as
culture medium.
At culture passage 2 (P2) cells were frozen at 5 × 106 cells/ml
in Cryostor R© CS10 (BioLife Solutions, StemCell Technologies,
Canada) to constitute the MCB, consisting of 1 ml aliquots in
1.8 ml Nunc cryovials (Thermo Fisher Scientific). A controlled
rate biological freezer was used (Biofreeze R© BV45, Consartic,
Germany) and the vials were stored in liquid nitrogen gas
phase.
A fraction of the cells were maintained in culture for a
further four passages (up to P6), to constitute the PPCB,
which was frozen (same conditions used for the MCB) for QC
purposes.
Large-Scale Manufacturing of
GMP-Exo-CPC
For each manufacturing run, frozen CPC from MCB (P2) were
thawed and cultured (8–10 × 104 cells/cm2 initial seed) in
StemMACS-MSC expansion Media kit XF or MSC-Brew GMP
Medium, to obtain 16 CellBIND R©Hyperflask R© culture vessels. At
P4, the medium was removed, the culture vessels were washed
twice with DPBS, then the production medium was added (about
500 ml/vessel). After 14 days at 37◦C 5% CO2, the CM was
collected (total 8 l) in sterile bottles (Corning).
The EPC harvested after CM collection were frozen
(3.3 × 106 cells/ml, same freezing medium used for the
MCB) for QC purposes.
The Exo isolation was carried out in a closed system using the
ÄKTATM Flux 6 instrument (previously sanitized according to
the manufacturer’s instructions), through the following process
phases:
(1) CLARIFICATION: the CM-containing bottles were
connected to the instrument circuit for clarification
through a ULTA Pure HC 0.6/0.2 µm Capsule Filter (GE
Healthcare); the instrument transfer pump was used and
the clarified CM was collected directly in the instrument
tank (process vessel).
(2) CONCENTRATION: the activation of the instrument feed
pump initiated the concentration by TFF. Instrument
parameters (flow rate, transmembrane pressure) were set,
according to manufacturer’s instructions, to minimize the
“shear stress” in order to preserve Exo integrity. The
permeate, containing components below the 300 kDa cut-
off, was collected in a waste container, while the retentate
(enriched in Exo) was recirculated to the process vessel. At
300–500 ml, the concentration was stopped.
(3) DIAFILTRATION: the concentrated CM contained in the
process vessel was diluted in formulation buffer (Plasma-
Lyte A R© solution, total five volumes in five diafiltration
cycles), with the aim to obtain a replacement of the
initial production medium greater than or equal to 95%.
The diluted solution was concentrated through the same
hollow fiber cartridge used for the previous phase, until
reaching a 200–300 ml volume in the process vessel.
(4) RECOVERY: the solution contained in the process vessel
and in the instrument circuit was harvested through the
bottom sample port in a post-process bag.
(5) STERILIZING FILTRATION: the post-process bag was
connected to the instrument circuit for sterilizing filtration
through a Sterile Millipak R©-20 Filter Unit 0.22µm (Merck
Millipore); the instrument transfer pump was used and
the sterile product (275–350 ml) was collected directly in
a final product bag.
(6) FILLING: the final product was filled in 0.5, 1, and 3 ml
aliquots in 1.8 and 4.5 ml Nunc cryovials (Thermo Fisher
Scientific), as appropriate. The vials were frozen and
stored at−80◦C, as GMP-Exo-CPC.
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CPC Count
Frozen aliquots of MCB, PPCB, and EPC were thawed and
cell counting was performed with the EVETM Automated Cell
Counter (NanoEnTek Inc., United States). The same system was
used for in process controls (cell number and viability) during
CPC culture.
CPC Immunophenotype Analysis
Surface markers expressed on CPC were analyzed by flow
cytometry using the MSC Phenotyping Kit human (Miltenyi
Biotec GmbH) and MACSQuant Analyzer (Miltenyi Biotec
GmbH).
CPC Apoptosis Analysis
The BD PharmingenTM Annexin V FITC apoptosis detection
kit (Becton Dickinson, United States) was used according to
manufacturer’s instructions. In the flow cytometry plots, the
following cell populations were identified: viable = annexin V
negative/PI negative; early apoptotic = annexin V positive/PI
negative; late apoptotic/necrotic = annexin V positive/PI positive
plus annexin V negative/PI positive.
CPC RT-PCR
The expression of transcription factors was evaluated by RT-PCR.
The genes GATA4 (Gene ID: 2626), TBX5 (Gene ID:
6910), TBX18 (Gene ID: 9096), and MESP1 (Gene ID: 55897)
were selected according to literature data (Gallagher et al.,
2014; Palpant et al., 2015) as CPC markers, representing
mesodermal (TBX5, TBX18) and cardio-specific (GATA4,
MESP1) transcription factors. As reverse transcription and
amplification controls, primers on the GAPDH gene (Gene ID:
2597) were used.
Nanoparticle Tracking Analysis
Exo-CPC particles were evaluated by NTA, with the instrument
NanoSight LM10 (Malvern Instruments, United Kingdom).
Measurement of Total Protein Content
The QuantiProTM BCA Assay kit (Sigma-Aldrich/Merck) was
used for total protein quantification; the samples underwent three
freeze/thaw cycles to break Exo structure immediately before
running the assay.
Measurement of TSG101 Content
The “Human TSG101 ELISA Kit (Sandwich ELISA) – LS-F8581”
(LSBio LifeSpan Biosciences Inc., United States) was used for
TSG101 content quantification. The samples underwent three
freeze/thaw cycles to break Exo structure immediately before
running the assay (Kim et al., 2005).
Flow Cytometry Analysis of Exosome
Surface Markers
To characterize Exo surface markers, the MACSPlex Exosome
Kit (Miltenyi Biotec GmbH) was used following manufacturer’s
instructions. Fluorescence was measured by the MACSQuant
analyzer.
Transmission Electron Microscopy
(TEM) – Negative Staining
Sample aliquots were absorbed on glow-discharged
carbon-coated formvar nickel grids and negatively stained
with uranyl acetate. The grids were examined by Talos L 120C
electron microscope at 120 kV.
Protein Isolation and Western Blot
Analysis
Total proteins were extracted by lyzing exosomes or cells in
the presence of protease inhibitors. Proteins were separated on
gel and transferred onto a PVDF membrane. Anti-Periostin
(Santa Cruz, United States), anti-TSG101, anti-GRP94, and
anti-GAPDH (Abcam, United Kingdom) were used as primary
antibodies; IRDye R© 680RD or 800CW goat anti-mouse or goat
anti-rabbit (LI-COR Biosciences, United States) as secondary
antibodies. The infrared signal was detected using the Odyssey
CLx Detection System (LI-COR Biosciences).
Sterility Test
The sterility test (Microbiological Control for Cellular Products,
Eu. Ph 2.6.27) was carried out on MCB, PPCB, EPC, and
GMP-Exo-CPC using an automated microbial detection system
(BACT/ALERT 3D, bioMérieux, France).
Bacterial Endotoxins Test
The bacterial endotoxins were tested in the MCB, PPCB, EPC,
and GMP-Exo-CPC samples according to Eu. Ph. 2.6.14, using
the endosafe R©-PTSTM system (Charles River, United States).
Exosome Functional Assays
The anti-apoptotic activity of Exo was tested by an in vitro
apoptosis/viability assay developed in house, based on the use
of CPC and staurosporine (Sigma-Aldrich/Merck) as apoptosis
inducer. Exo were added at different concentrations; vehicle
(Plasma-Lyte A R© solution) and/or Exo from normal human
dermal fibroblasts (Exo-F) were used as controls. Cells were
stained with calcein and PI (Thermo Fisher Scientific) and
fluorescence was measured as representative for viability and
apoptosis, respectively.
The pro-angiogenic activity of Exo at different concentrations
was measured by the V2a Kit (Cellworks, United Kingdom)
according to manufacturer’s instructions. Tubule formation was
visualized by optical microscopy and total tube length was
determined. A quantification of CD31 expression was also
performed.
Animal Experiments
Myocardial ischemia was induced in healthy male Wistar
rats (250–300 g body weight) anesthetized with a cocktail of
tiletamine and zolazepam (40 mg/kg given intraperitoneally;
Zoletil100, Virbac, France), intubated, and ventilated. The left
anterior descending artery was ligated near its origin with a
4-0 silk suture. Thirty minutes after permanent coronary artery
occlusion, the peri-infarct myocardial region was injected at three
different points with a total of 100 µl Plasma-Lyte A R© containing
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1 × 1011 GMP-Exo-CPC particles (n = 10) or Plasma-Lyte A R©
only (vehicle) as control (n = 5). The Exo concentration used was
optimized based on previous dose–response studies.
In the sham-operated group (n = 5), the left coronary artery
was not ligated. The chest was then closed, pneumothorax
was reduced, and the rats were treated with meloxicam during
postsurgical recovery. Sedated rats underwent transthoracic
echocardiography at 7 and 28 days post-MI using the Vevo2100
echocardiography system (VisualSonic System) equipped with a
12-MHz linear transducer. Under ECG monitoring of heart rate,
2D images of the hearts were acquired in long-axis and short-axis.
LVEF was measured with the biplane Simpson’s method; LVESV
and LVEDV were also determined. Echocardiograms were
evaluated by two independent examiners blind to the treatment
protocol.
Statistical Analysis
All the data were expressed as the mean± SD.
Student’s t-test was used for the comparison of two groups.
In case of multiple groups, one-way analysis of variance was
performed, and the following pairwise comparisons were tested
with the Student’s t-test, correcting the alpha according to
the number of planned comparisons (Bonferroni correction).
Statistical significance was accepted for p-values < 0.05 (∗),
<0.01 (∗∗), or <0.001 (∗∗∗).
RESULTS
Definition of Optimal GMP Grade
Conditions for CPC Isolation and Culture
CPC Can Be Efficiently Isolated and Expanded in
GMP Grade Xeno-Free Conditions
Three different CPC isolation and culture methods were
compared, as summarized in Table 1.
Cardiac progenitor cells were successfully isolated from heart
tissue fragments in all the tested conditions, as shown in
Figure 1A for a representative donor. The morphology of
outgrowing GMP grade cells, both CPC-I and CPC-II (panels a
and b) was similar to that of research grade cells CPC-R (panel c).
During cell expansion, at confluence, CPC-I and CPC-II (panels d
and e) appeared smaller and more actively replicating than CPC-
R (panel f). The higher replication rate of GMP grade cells is
indeed evidenced by the growth curves of CPC-I and CPC-II,
when compared to that of CPC-R (panel g). Moreover, both CPC-
I and CPC-II showed regular cell growth up to culture passage 8
(P8), whereas the CPC-R culture was stopped after five passages
only, as the cells were no longer able to adhere properly to the
culture flasks.
The higher growth rate of CPC-I and CPC-II in respect to
CPC-R was confirmed analyzing parallel cultures derived from
five different donors: Figure 1B shows that the mean doubling
time was significantly lower for CPC-I (52 h) and CPC-II (61 h)
than for CPC-R (105 h).
Figure 1C refers to five different donors, in which the initial
heart tissue specimen was divided in two to three equal aliquots,
each processed in a distinct condition. No difference was detected
in the number of CPC harvested in different conditions.
Overall, these data indicated that both the “GMP grade I” and
“GMP grade II” conditions were suitable for CPC isolation and
expansion.
The “GMP grade I” condition was chosen for scale-up
experiments based on empirical considerations: in the first step
for CPC isolation (Figure 9 and Supplementary Figure S5), the
heart tissue fragments appeared to adhere more tightly to the
plastic in “GMP grade I” than in “GMP grade II” condition,
facilitating the manipulation process.
CPC Cultured in GMP Grade Conditions Stably
Express MSC Markers as Well as Mesodermal- and
Cardiac-Specific Transcription Factors
Cardiac progenitor cells cultured in both research- and GMP-
grade conditions expressed typical mesenchymal stem cell
markers (CD73, CD90, CD105), and not hematopoietic markers,
when analyzed before starvation for Exo release (Figure 2A,
PRE). The expression was maintained during Exo production
(Figure 2A, POST). Curiously, CD90 was less expressed and
CD105 showed a higher variability in CPC-R than in CPC-I and
CPC-II. A representative profile of surface markers expression on
CPC-I, before (PRE) and after (POST) the starvation for exosome
release, is shown in Figure 2B.
The same CPC were tested for the expression of mesodermal
(TBX5, TBX18) and cardiac specific (GATA4, MESP1)
transcription factors by RT-PCR: the expression was maintained
in all the conditions, before (PRE) and after (POST) starvation
for exosome production (Figure 3).
CPC Cultured in GMP Grade Conditions Release Exo
To evaluate the ability of CPC cultured in different conditions
to release Exo, CM samples were concentrated and analyzed
by NTA.
As shown in Figure 4, all CPC were releasing particles showing
the typical size distribution of Exo vesicles, with peaks in the
111–116 nm range, which fits with the 30–150 nm size range
described in literature (Shedden et al., 2003; Cervio et al., 2015;
Barile et al., 2017b; Sluijter et al., 2018).
No differences were observed in size distribution among the
Exo produced by CPC cultured under the different conditions.
In western blot analysis (Supplementary Figure S1), the
specific Exo marker TSG-101 and Periostin, a protein enriched
in CPC-derived EV (Gouin et al., 2017), were detected in Exo
preparations from CPC-I, CPC-II, and CPC-R, while the cell
marker GRP94 was not present.
Flow cytometry analysis (Supplementary Figure S2) showed
that Exo from CPC cultured in all the conditions expressed Exo
markers (CD9, CD63, CD81) as well as CD105 and CD44, typical
of CPC.
Exo Derived From CPC Cultured in GMP Grade
Conditions Mediate Anti-apoptotic Activity
Exo produced by cells expanded in different conditions were
analyzed for their functional activity, in terms of CPC protection
from staurosporine-induced apoptosis (Figure 5). As shown in
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FIGURE 1 | Isolation and culture of CPC. (A) Representative images of CPC outgrowth from cardiac fragments (a–c) and CPC expansion (d–f), under the GMP
grade methods I and II (CPC-I and -II) and the research grade method (CPC-R). The cumulative population doublings (CPD) over time is also shown (g) for the same
representative experiment. (B) Doubling times (mean + SD, n = 5) of CPC cultured in the different conditions. NS, not significant; ∗p < 0.05, one-way ANOVA with
Student’s t-test with Bonferroni correction. (C) CPC number at harvest from the outgrowth plates, by culture conditions. CPC-I and -II: n = 5; CPC-R: n = 3.
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FIGURE 2 | FACS analysis of CPC cultured in different conditions. (A) Comparison of surface markers expression on CPC cultured in GMP conditions (CPC-I and -II,
n = 5) or research conditions (CPC-R, n = 3), before (PRE) and after (POST) 7-day in vitro starvation for Exo production. Bars: mean + SD. (B) Histogram plots of
surface markers expression of CPC-I, before (PRE) and after (POST) starvation for Exo production. Gray peaks: staining with isotype control antibodies; black peaks:
staining with antibodies specific for the reported markers.
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FIGURE 3 | RT-PCR analysis of CPC cultured in different conditions. Mesodermal markers: TBX5 and TBX18; cardiac markers: GATA4 and MESP1. CPC samples
were taken before (PRE) and after (POST) starvation for Exo production. Positive control: cardiac tissue. Amplification control: GAPDH. Negative controls (run in
duplicate): reverse transcription negative sample with GAPDH primers. Gel images were cut above the primer dimers bands.
Figure 5A, cells cultured in the presence of Exo produced by both
CPC-I (Exo-CPC-I) and CPC-R (Exo-CPC-R) showed higher
level of viability (30 ± 5 and 22 ± 11%, respectively) compared
to controls (vehicle, 5 ± 1%, and Exo-F, 5 ± 1%). Accordingly,
cell death was reduced with both Exo-CPC-I and Exo-CPC-R
(4± 11 and 76± 6%) in respect to vehicle (116± 14%) or Exo-F
(113± 8%; Figure 5B).
The protective effect of Exo-CPC was also observed on HL-1
cardiomyocytic cells (Supplementary Figure S3).
Exo-CPC: Upstream Process
Optimization and Scale-Up
To optimize the Exo production phase (the upstream process),
CPC expanded in culture up to P4 were starved in production
medium for different times and in different scales, from 15 ml
to 8 l.
As a quantitative indicator of Exo release in different
conditions, the Exo-specific TSG101 protein was tested in CM
extracts; total protein content was also determined as a measure
of unspecific contamination.
Figure 6A indicates that, despite intra-sample variations,
TSG101 was consistently detected in CM harvested after 7 days
of starvation (15 ml scale, n = 6) from both CPC-I and CPC-II.
As reported above, CPC-I condition was chosen for scale-up.
Figure 6B shows that TSG101 was detected in CM harvested after
7 days of starvation in the whole scale range, from 15 ml to 8 l.
Time course experiments were performed with CPC-I in the
500 ml (n = 1) and 8 l (n = 2) scales (Figure 6C): the TSG101
content was significantly increased at 2 weeks, while the total
protein content was stable.
After 1 as well as 2 weeks in production medium, CPC-I
appeared healthy and well adherent (Supplementary
Figure S4A), and they maintained their phenotypic
characteristics (Supplementary Figure S4B). No relevant
levels of apoptosis were detected (Supplementary Figure S4C).
CPC-I floating non-adherent cells were counted after 14 days
starvation, and found to represent 5% of the total cells. These
data indicate that the serum-free production medium guarantees
the survival of the large majority of cells for up to 14 days, while
maintaining their characteristics.
Based on these results, the starvation time for large-scale
GMP-Exo-CPC production was set to 14 days.
Exo-CPC: Downstream Process
Optimization and Scale-Up
To proceed toward Exo-CPC isolation (the downstream process),
the CM was first clarified in order to remove cell debris and
aggregates, through centrifugation and/or 0.22 µm filtration
(details in the section “Materials and Methods”).
Concentration through membranes with defined cut-off was
then performed, with the aim of retaining Exo in the concentrate,
while removing liquid and contaminants.
To follow Exo recovery throughout the process, the Exo-
specific TSG101 protein was tested in extracts from “in process”
samples collected at different points; total protein content was
also determined, as impurity indicator.
As shown in Figure 7A, two different filtration systems were
tested, in different scales, from 15 ml to 8 l of CM: direct filtration
(scales: 15 and 65 ml, three experimental runs each, CM collected
after 1 week starvation) and TFF (scales: 2 l, three runs, CM
collected after 1 week starvation, and 8 l, two runs, CM collected
after 2 weeks starvation). Up to about 500 ng of TSG101 were
loaded on direct filtration (panels a and b), obtaining around
240 ng of TSG101 after concentration; up to about 140 µg of
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FIGURE 4 | NTA profiles of Exo released by CPC cultured in different conditions. Size distribution graphs of the Exo from CPC expanded in GMP and research
conditions. Red error bars indicate ±1 standard error of the mean. The mean ± standard error (n = 5) of the distribution modes from each replicate are shown.
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FIGURE 5 | In vitro anti-apoptotic activity of Exo released by CPC cultured in different conditions. Apoptotic agent: 1 mM staurosporine. CRL + = 10% FBS; black
dotted bars = Exo-CPC-I and control (vehicle = Plasma-Lyte A R©); white dotted bars = Exo-CPC-R and control (Exo-F). Exo were added at 3 × 107 particles/ml
(100 µl/well), while the vehicle was added at the same volume as Exo-CPC-I. (A) Results from calcein staining. The treatment with complete medium +
staurosporine is the 100% survival reference. (B) Results from PI staining. The treatment with the basal medium + staurosporine is the 100% cell death reference.
Bars: mean + SD (n = 5). NS, not significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, one-way ANOVA with Student’s t-test with Bonferroni correction.
TSG101 were loaded on TFF (panels c and d), obtaining around
120 µg of TSG101 after concentration. Consistent total protein
removal was observed in both systems.
In the TFF system, diafiltration was also performed after
concentration, in order to formulate Exo-CPC in Plasma-Lyte
A R©, a solution suitable for in vivo administration in humans.
The yields of single process runs are shown in Figure 7B. The
best performing process was 8 l TFF, which guaranteed a TSG101
yield of at least 89%, with a concomitant total protein removal of
97–98%.
Based on these results, TFF was selected as the method of
choice for large-scale isolation of GMP-Exo-CPC.
Generation of CPC Master Cell Bank and
Post-production Cell Bank
Heart tissue specimen from a dedicated donor was processed
exclusively for CPC banking in the selected GMP condition
(“GMP grade I”).
At day 15 after the seeding of tissue fragments, about
4.6 × 106 CPC were harvested and expanded for 36 days up to
1.4 × 108 cells at P2, then frozen to constitute the MCB. A small
fraction of the same cells (5 × 106) were reseeded and expanded
until culture passage 6 (P6), then frozen as PPCB. This last cell
bank was generated for QC purposes only, in order to check the
quality of the CPC maintained in culture well beyond P4, the
passage when the production of Exo was planned. Regulatory
guidelines (I.C.H., 2018) indeed require the analysis of PPCB
(“cells at the limit of in vitro cell age used for production”),
together with the MCB, to evaluate the stability of the cells in
culture conditions.
Master cell bank and PPCB were then tested according to
a defined QC plan. As explained more in detail in Section
“Discussion,” the approval for the preclinical or clinical use is
based on criteria (the specifications) defined for each QC test. The
results of such exhaustive testing are shown in Table 2.
All the results met the specifications: both MCB and PPCB
were sterile, negative for bacterial endotoxins and mycoplasma
(the safety tests). They had good viability (the potency test)
and they were positive for mesenchymal markers, negative for
hematopoietic surface markers, and expressed the mesodermal
and cardiac-specific transcription factors (the identity tests).
On this basis, the MCB was approved for the large-scale
production of GMP-Exo-CPC to be used in preclinical studies.
Large-Scale Manufacturing of
GMP-Exo-CPC
The whole process is summarized in Figure 8. The results of two
full scale production runs are shown here below.
Upstream Process: CM Production
Two full scale runs were conducted. For each run, two MCB
aliquots were thawed (about 1× 107 cells) and expanded in vitro
up to P4 (total cell culture surface > 2.5 m2). About 1 × 108
cells (first run: 0.9 × 108, second run: 1.2 × 108) were seeded,
expanded in culture medium until confluence, then induced to
release Exo by starvation in production medium for 2 weeks.
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FIGURE 6 | Optimization and scale-up of Exo-CPC production. (A) TSG101 content and total protein content in CM from CPC-I and -II. Production scale: 15 ml;
cells starved for 7 days before medium collection. Each dot represents the analyte concentration in CM from a single culture. (B) TSG101 content and total protein
content in CM from CPC-I on different culture volumes; cells starved for 7 days before medium collection. Each dot represents the analyte concentration in CM from a
single culture. (C) Time course of TSG101 and total protein content in CM collected from CPC-I at 1 week (7 ± 1 days) and 2 weeks (14 ± 1 days) during starvation.
Production scale: 0.5 and 8 l. Paired Student’s t-test at 2 weeks versus 1 week starvation: p < 0.05 for TSG101 content, not significant for total proteins content.
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FIGURE 7 | Optimization and scale-up of Exo-CPC isolation. (A) Quantitative analysis of TSG101 and total proteins before and after concentration (a–d) and
diafiltration (c,d) by different techniques. Mean + SD with n = 3 (a–c; CM collected after 1 week starvation) or n = 2 (d, CM collected after 2 weeks starvation).
(B) TSG101 and total protein recovery as a percentage of the quantity measured in the initial CM (pre-concentration). Each dot is the result of an independent
experiment. Pre-c, before concentration; post-c, after concentration; post-d, after diafiltration.
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TABLE 2 | Quality control of CPC master cell bank and post-production cell bank.
Parameter Method Specifications Results
MCB PPCB
Sterility Microbiological control for cellular products Absence of growth Absence of growth Absence of growth
Bacterial endotoxin (EU/ml) Quantitative LAL test <5.0 <5.0 <5.0
Mycoplasma PCR Negative Negative Negative
Cell concentration (cells/ml) Trypan blue, automated cell counting ≥4 × 106 4.48 × 106 4.88 × 106
Cell viability (%) ≥70 78 86
CD90 (% positive cells) Flow cytometry ≥90.0 99.0 99.8
CD105 (% positive cells) ≥90.0 95.8 95.6
CD73 (% positive cells) ≥90.0 96.3 99.7
CD14/20/34/45-HLA DR (% positive cells) <10.0 5.6 7.6
GATA4 expression (mRNA) RT-PCR Positive Positive Positive
TBX5 expression (mRNA) Positive Positive Positive
TBX18 expression (mRNA) Positive Positive Positive
MESP1 expression (mRNA) Positive Positive Positive
About 8 l of Exo-containing CM were collected, containing 20.6
(first run) and 16.1 (second run) ng/ml TSG101.
After CM collection, cells were harvested (first run: 5.9× 108,
second run: 7.2 × 108 cells) and part of them (9 × 107
corresponding to 1/6–1/8 of the total cell number) were frozen
as EPC.
Downstream Process: GMP-Exo-CPC Isolation
Exo were isolated as summarized in Figure 8 and detailed in
Section “Materials and Methods.”
The two full scale runs yielded 2.9 × 1013 and
3.1 × 1013 exosome particles (corresponding to 100 µg
and 75 µg of TSG101, respectively), in final formulation
buffer.
The final solutions containing the Exo were aliquoted in
cryovials and frozen at −80◦C, to constitute GMP-Exo-CPC Lot
1 and Lot 2, respectively.
GMP-Exo-CPC Quality Control
The results of the exhaustive QC testing of GMP-Exo-CPC are
shown in the first section of Table 3.
All the results met the specifications: both lots were
sterile and negative for bacterial endotoxins (safety tests).
Moreover, they contained Exo of the expected size expressing
FIGURE 8 | Large-scale GMP-Exo-CPC production chart. The upstream and downstream processes are grouped by the dotted boxes. See Section “Materials and
Methods” for details.
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TABLE 3 | Quality control of GMP-Exo-CPC lots and EPC.
GMP-Exo-CPC
Parameter Method Specifications Results
GMP-Exo-CPC lot 1 GMP-Exo-CPC lot 2
Sterility Microbiological control for cellular products Absence of growth Absence of growth Absence of growth
Bacterial endotoxin (EU/ml) Quantitative LAL test <5.0 <5.0 <5.0
TSG101 (ng/ml) ELISA FIO 285 272
Total proteins (µg/ml) BCA assay FIO 1008 840
Particle concentration (p/ml) Nanoparticle tracking analysis FIO 8.26 × 1010 1.12 × 1011
Particle size (nm) 50–150 121 143
CD9 expression Flow cytometry Positive Positive# Positive#
CD63 expression Positive Positive# Positive#
CD81 expression Positive Positive# Positive#
EPC
Parameter Method Specifications Results
EPC lot 1 EPC lot 2
Sterility Microbiological control for cellular products Absence of growth Absence of growth Absence of growth
Bacterial Endotoxin (EU/ml) Quantitative LAL test <5.0 <5.0 <5.0
Mycoplasma PCR Negative Negative Negative
Cell concentration (cells/ml) Trypan blue, automated cell counting >2 × 106 2.24 × 106 2.37 × 106
Cell viability (%) ≥70 81 87
CD90 (% positive cells) Flow cytometry ≥90.0 97.3 94.6
CD105 (% positive cells) ≥90.0 98.8 96.6
CD73 (% positive cells) ≥90.0 99.7 99.01
CD14/20/34/45-DR (% positive cells) <10.0 6.7 2.87
GATA4 expression (mRNA) RT-PCR Positive Positive Positive
TBX5 expression (mRNA) Positive Positive Positive
TBX18 expression (mRNA) Positive Positive Positive
MESP1 expression (mRNA) Positive Positive Positive
FIO: for information only; #see Figure 9.
the CD9, CD63, and CD81 surface markers (identity/purity
tests).
Extended surface marker characterization (Figure 9A) showed
that the GMP-Exo-CPC also expressed CD105 and CD44,
antigens typical of CPC, as well as CD146, that was already
detected on Exo-CPC-R (Barile et al., 2014).
A number of other markers were not expressed, including
HLA and hematopoietic antigens. The full list of markers
evaluated is reported in Supplementary Table S1.
GMP-Exo-CPC were also analyzed by TEM, and
representative images are shown in Figure 9B. Western
blot analysis (Supplementary Figure S1) was performed to
detect the specific Exo marker TSG-101, Periostin, a protein
enriched in CPC-derived EV (Gouin et al., 2017), as well as the
cell marker GRP94, used as an indicator of cell contaminants
from cell culture. TSG101 was consistently detected in Exo
preparations and cell lysate. Periostin was strongly enriched
in Exo and was not detectable in cell lysate. GRP94 was
consistently detected in CPC and poorly, if not, present onto
Exo, suggesting lack of substantial contamination by cell
debris.
The GMP-Exo-CPC lots were also tested for TSG101 content
(a further identity test), total protein content (purity test), and
particle concentration.
Moreover, in vitro and in vivo functional activities were
assessed as described below (potency test).
GMP-Exo-CPC Mediate Anti-apoptotic Activity
in vitro
To test the anti-apoptotic activity of GMP-Exo-CPC, the same
apoptosis/viability assay above described was used.
As depicted by the images from representative wells
(Figure 10A) and by calcein AM staining results (Figure 10B),
cells treated with Exo at the 5 ng/ml dose showed higher
viability than cells treated with vehicle alone (GMP-Exo-CPC
0.5 ng/ml: 14± 13%, GMP-Exo-CPC 5 ng/ml: 41 ± 11%, vehicle
8± 4%).
In agreement with calcein experiment data, the addition of
Exo protected CPC from cell death, as shown in Figure 10C
by the PI staining results (GMP-Exo-CPC 0.5 ng/ml:
86 ± 10%, GMP-Exo-CPC 5 ng/ml: 46 ± 9%, vehicle
105± 25%).
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FIGURE 9 | Characterization of GMP-Exo-CPC. (A) Flow cytometry analysis. Two lots of GMP-Exo-CPC were analyzed with the MACSPlex Exosome Kit. Data are
represented as APC mean fluorescence intensity normalized to the mean signal intensity obtained with the anti-CD9, anti-CD63, and anti-CD81 beads.
(B) Representative TEM images.
In both calcein AM and PI readouts, the protective effect of
Exo was dose-dependent and, at the highest dose, statistically
significant if compared to the vehicle.
GMP-Exo-CPC Mediate Pro-angiogenic Activity
in vitro
The pro-angiogenic activity of GMP-Exo-CPC was tested by
measuring the length of tubules and the expression of the CD31
marker induced in human umbilical endothelial cells.
Pictures of CD31-stained cells in different conditions are
shown in Figure 11A and total tube lengths in Figure 11B
(GMP-Exo-CPC 3 ng/ml: 60% for GMP-Exo-CPC Lot 1 and 80%
for GMP-Exo-CPC Lot 2, GMP-Exo-CPC 15 ng/ml: 82% for
GMP-Exo-CPC Lot 1 and 109% for GMP-Exo-CPC Lot 2, vehicle:
23 and 31%).
CD31 expression was higher in cells treated with Exo than in
in cells exposed to vehicle (Figure 11C; GMP-Exo-CPC 3 ng/ml:
91% for GMP-Exo-CPC Lot 1 and 94% for GMP-Exo-CPC
Lot 2, GMP-Exo-CPC 15 ng/ml: 127% for GMP-Exo-CPC Lot
1 and 127% for GMP-Exo-CPC Lot 2, vehicle: 63 and 63%).
No statistical analysis was possible due to the low number of
experiments.
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FIGURE 10 | In vitro anti-apoptotic activity of GMP-Exo-CPC. Apoptotic agent: 1 mM staurosporine. CRL + = 10% FBS; GMP-Exo-CPC doses: 0.5 and 5 ng of
TSG101/ml (100 µl/well); vehicle = Plasma-Lyte A R© added at the same volume as GMP-Exo-CPC. (A) Representative images at 10x magnification of the cells after
the indicated treatments. (B) Results from calcein staining. The treatment with the complete medium + staurosporine is the 100% survival reference. (C) Results
from PI staining. The treatment with the basal medium + staurosporine is the 100% cell death reference. Bars: mean + SD (n = 5). NS, not significant, ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001, one-way ANOVA with Student’s t-test with Bonferroni correction.
GMP-Exo-CPC Show Therapeutic Efficacy in a Rat
Preclinical Model
The functional activity of GMP-Exo-CPC was confirmed in vivo,
in a rat model of permanent coronary artery occlusion
(Figure 12).
GMP-Exo-CPC significantly improved LVEF after
4 weeks, whereas the vehicle alone was not effective
(Figure 12B).
Moreover, GMP-Exo-CPC treatment was associated with a
significantly lower increase of LVESV compared with vehicle at
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FIGURE 11 | In vitro pro-angiogenic activity of GMP-Exo-CPC. GMP-Exo-CPC doses: 3 and 15 ng of TSG101/ml (0.5 ml/well). CRL + = VEGF; CRL – = suramin;
vehicle = Plasma-Lyte A. (A) Representative images at 4x magnification of cells after the indicated treatments. CD31-stained tubules are visible in black. (B) Total
tubule length detected by the AngioSys 2.0 Image Analysis Software. The mean length in VEGF treated cells was set to 100%. (C) CD31 expression detected by
ELISA. The expression in VEGF treated cells was set to 100%.
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1 as well as 4 weeks (Figure 12C), while LVEDV was not affected
(Figure 12D).
EPC Quality Control
As the GMP-Exo-CPC lots, the corresponding EPC underwent
various QC tests, reported in the second section of Table 3.
All the results met the specifications: cells collected after both
production runs were sterile, negative for bacterial endotoxins
and mycoplasma, viable, positive for mesenchymal and negative
for hematopoietic surface markers, as well as positive for
mesodermal and cardiac-specific transcription factors.
DISCUSSION
Exo as Therapeutic Tools
Exo from different cell types are being tested in clinical trials in
several therapeutic areas, including cancer, diabetes, and wound
healing (Lener et al., 2015; Barile and Vassalli, 2017; Sluijter
et al., 2018). The safety and feasibility of the approach has
been demonstrated in phase I–II immunotherapy studies for
colon rectal cancer, melanoma, and non-small cell lung cancers
using Exo from dendritic cells pulsed with tumor antigens; no
relevant adverse events occurred and partial clinical responses
were detected in some patients (Pitt et al., 2016).
Based on these encouraging results, Exo-based therapies
may well be considered for other applications, including
cardiovascular diseases (Barile and Vassalli, 2017; Barile et al.,
2017b; Xu et al., 2017; Sluijter et al., 2018).
Exo released by CPC (Barile et al., 2012) have already
shown a clear therapeutic potential: they inhibit cardiomyocyte
apoptosis and promote angiogenesis in vitro, as well as reduce
tissue damage, inhibit cardiomyocyte apoptosis, and promote
angiogenesis in vivo, improving post-infarction cardiac function
in a preclinical rat model of AMI (Barile et al., 2014).
Similarly, others have shown the beneficial effects of Exo
released by CDC in AMI preclinical models in rats (Ibrahim et al.,
2014) and pigs (Gallet et al., 2017).
CDC are considered cardiac progenitors derived from,
but not identical, to CPC (Barile et al., 2017a). CDC by
FIGURE 12 | In vivo therapeutic effect of GMP-Exo-CPC. (A) Representative echocardiographic M-mode images of hearts injected with vehicle and GMP-Exo-CPC,
taken at day 28 after MI. (B) LVEF in sham-operated rats at day 28 (SHAM, n = 5), in GMP-Exo-CPC injected rats (black bars, n = 10), and vehicle injected rats (gray
bars, n = 5) 7 and 28 days after MI. Bars: mean + SD. Measurements of LVESV (C) and LVEDV (D) in GMP-Exo-CPC injected rats (black line) and vehicle injected
rats (gray line) 24 h, 7 and 28 days after MI. Mean ± SD is shown. Vehicle = PlasmaLyte A R©. ∗p < 0.05, Student’s t-test.
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themselves have shown safety and potential efficacy in
autologous cell therapy in humans, in a phase-I AMI clinical
study (Makkar et al., 2012; Malliaras et al., 2014); they are
now being tested in allogeneic contexts, in phase I-II trials
for AMI (ClinicalTrials.gov Identifier: NCT01458405), dilated
cardiomyopathy (ClinicalTrials.gov Identifier: NCT02293603),
and Duchenne muscular dystrophy cardiomyopathy
(ClinicalTrials.gov Identifier: NCT02485938). As Exo were
identified as key mediators for the regenerative effects of CDC,
trials with CDC-derived Exo are currently being planned (Gallet
et al., 2017).
Exo-CPC as a New Medicinal Product
To move toward clinical application in humans, Exo-CPC need
to be developed as a novel medicinal product, according to the
pertinent regulatory guidelines. Like other EV-based products,
Exo should be considered as biological medicines, falling into the
category of biopharmaceuticals as defined in EU, United States,
and Australia (Lener et al., 2015; I.C.H., 2018). However, at
variance with other biopharmaceuticals such as recombinant
proteins or antibodies, EV are complex entities and may have
much in common with their cell source. For this reason,
the development of EV-based therapeutics should take into
consideration not only the regulations for biologicals, but also
those for cell based products and ATMP as defined in Lener et al.
(2015).
The aim of the present work was indeed the development of
production and QC methods for the large-scale preparation of
Exo-CPC as a medicinal product, in accordance with current
GMP. The focus has been set on both the cell source (CPC) and
the product itself (Exo-CPC).
The starting point for development activities were the research
grade methods used so far for isolation and culture of CPC
and for small-scale production of Exo-CPC for pilot preclinical
studies (Barile et al., 2014, 2018). Our approach has been focused
on overcoming the main limitations of such methods: use of
open culture vessels, poorly standardized reagents containing
animal-derived components, hardly scalable steps.
On the analytical side, research grade CPC and Exo-CPC
were not tested for safety. Sterility, endotoxin and mycoplasma
assays were included in the QC panel for CPC cell banks
and GMP-Exo-CPC, in order to approve them for preclinical
studies in large animals. A more extensive safety panel,
including adventitious viruses, karyotype, cell senescence and
tumorigenicity, will be applied to next lots for first-in-human
trials.
The in vitro efficacy (potency) of research grade Exo-CPC was
tested by assays for anti-apoptotic and pro-angiogenic activity
(Barile et al., 2014, 2018). In order to achieve the reproducibility
and robustness required for their application in a GMP context,
they have been revisited and optimized throughout the present
work.
Objective of this work was also the establishment of a complete
QC strategy suitable to obtain clinical trial authorization by the
regulatory authority.
The approval of MCB as well as of GMP-Exo-CPC lots (release
for clinical use) is indeed based on passing a defined list of tests.
Each test result should fall within limits (specifications) defined at
compendial level for parameters such as endotoxin, mycoplasma,
and cell viability (European Pharmacopoeia, 2017), or set during
the development phase for other product characteristics, on the
basis of literature data and previous experimental results.
For example, the specifications for cell concentration for MCB,
PPCB (Table 2) and EPC (Table 3) have been defined taking
into consideration the concentration at which the cells had been
frozen. For the MCB and PPCB the freezing concentration was
5 × 106 cells/ml (see section “Materials and Methods”), thus
the specification for cell concentration after thawing was set at
4 × 106/ml, assuming a cell recovery of at least 80%, based on
previous lab results. For the EPC, the freezing concentration was
3.3 × 106 cells/ml, thus the specification for cell concentration
after thawing was set at 2× 106/ml, assuming a cell recovery of at
least 60%, based on previous lab results.
For some analytical parameters described here, the
specification could not be defined yet, and the results will
be collected FIO. This approach is in agreement with regulatory
guidelines (I.C.H., 2018) for early phase (I-II) clinical trials; for
advanced clinical phases, the specifications will be defined on the
basis of such FIO results.
Cell Source: CPC Derivation, Culture,
and Banking Strategy
In the research context, open culture vessels were used during the
initial tissue processing and for the adhesion of tissue fragments
until the harvest of outgrowing CPC; bovine gelatin was used
for the coating of culture vessels, FBS as supplement for culture
medium, and porcine trypsin as cell detachment reagent.
During development, special flasks with reclosable lids and
filter caps were introduced instead of dishes for the adhesion
of tissue fragments, to minimize contamination risks since the
beginning of the CPC growth.
Regarding the animal-derived reagents, regulatory authorities
recommend any possible effort to remove them from ATMP
processes, due to safety concerns. Moreover, it is well known that
FBS could contain bovine EV, which may contaminate Exo-CPC
preparations.
Several commercial serum-free culture media were tested as
potential substitutes for the FBS-containing medium; among
them, StemMACS-MSC expansion Media kit XF (Miltenyi
Biotec GmbH) was selected based on its ability to stably
support CPC growth, while maintaining cell characteristics. This
is a standardized, complete, xeno-free medium designed for
mesenchymal stem cells, that proved to be optimal for CPC;
of note, its GMP version is now available, certified for ex-vivo
therapeutic cell culture.
CELLstartTM CTSTM, containing only components of human
origin, and the fully synthetic Synthemax R© II-SC were chosen
as alternative adhesion substrates and tested for gelatin
replacement; among them, CELLstartTM CTSTM was eventually
preferred because of its slightly better effect on CPC yield and Exo
production. This reagent too is certified for ex vivo therapeutic
cell culture.
Trypsin was replaced by the properly certified TrypLETM
Select, a recombinant dissociation enzyme.
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In summary, all the selected reagents are of high quality and
properly certified, in line with regulatory expectations for ATMP
and related products (Solomon et al., 2016).
The newly defined culture conditions allowed large-scale CPC
expansion, up to 8 × 108 cells. A cell bank was generated and
approved for the production of GMP-Exo-CPC for preclinical
studies. A new MCB will be produced in the GMP certified
and classified area; it will be tested even more extensively
to be approved for the manufacturing of GMP-Exo-CPC for
first-in-man studies.
Additional tests will include in vitro and in vivo adventitious
viruses, culture assay for mycoplasma, tumorigenicity, cell
senescence, and karyotype.
Medicinal Product: GMP-Exo-CPC
Manufacturing
An essential issue for the future clinical application of Exo-CPC
is the possibility to produce and isolate Exo in large amounts
through a GMP compliant process.
So far, Exo for clinical applications were isolated by
polymer-based precipitation, ultracentrifugation, TFF, density
gradient or a combination of these methods, often applied
as separate and open manufacturing passages (Lener et al.,
2015; Konoshenko et al., 2018). Some of these technologies
may favor the concomitant concentration of impurities (e.g.,
precipitation, ultracentrifugation) or may be hardly scalable
(e.g., ultracentrifugation, density gradient; Xu et al., 2016). One
of the first, well-described GMP methods (Lamparski et al.,
2002) was developed for the production of dendritic cell-derived
clinical grade Exo; this protocol, based on TFF followed by
ultracentrifugation on sucrose density gradient, was successfully
applied on 1–4 l of CM, resulting in 35–65% Exo yield.
Our method for GMP-Exo-CPC manufacturing has been
implemented for 8 l of CM, but may be further scaled up,
using bioreactors for CPC culture and CM production, as well
as industrial TFF systems for Exo isolation. The absence of any
ultracentrifugation step simplifies the process, allowing high final
product yield (≥58%) with concomitant consistent reduction of
contaminants (total protein removal 97–98%).
Moreover, efforts were made to develop an integrated closed
circuit, encompassing the full downstream process (clarification,
concentration, diafiltration, and final sterilizing filtration) in a
single work station, the ÄKTATM flux 6 system (GE Healthcare).
The resulting GMP-Exo-CPC product contained about
3 × 1013 Exo particles, formulated in a clinical grade solution
(Plasma-Lyte A R©).
Such GMP-Exo-CPC were extensively characterized,
according to a well-defined QC strategy, including compendial
methods described in European Pharmacopoeia (2017), as well
as non-compendial product-specific methods developed or
optimized in house (manuscript in preparation) to achieve
suitable sensitivity, precision, accuracy, reproducibility,
and robustness, according to regulatory guidelines (I.C.H.,
2018).
Among several commercially available ELISA kits for exosome
proteins, the TSG101 ELISA used in this study was selected for
its sensitivity, allowing for the detection of even the lowest Exo
concentrations present in CM samples.
For purity evaluation, total protein content was determined,
assuming that most of the proteins contained in CM could be
soluble proteins, while a very small fraction of them could be
Exo components. In the GMP-Exo-CPC lots described here,
1 mg of proteins corresponded to 1.08 × 1011 ± 3.63 × 1010
particles. A product with similar purity (2.2 × 1011 particles/mg
of proteins) was successfully used by others in a large
animal preclinical study (Gallet et al., 2017): Exo from
CDC, injected directly into the heart muscle, were shown to
reduce scar area and improve LVEF in porcine acute and
chronic MI.
The potency of our GMP-Exo-CPC was demonstrated in vitro
analyzing their anti-apoptotic and pro-angiogenic activity and
confirmed in vivo in a rat model of permanent coronary artery
occlusion, where GMP-Exo-CPC significantly improved cardiac
function.
The in vitro potency assays were indeed designed with the
aim of predicting the in vivo activity in a repeatable and robust
fashion. In particular, the viability/apoptosis assay was developed
starting from the corresponding research grade assay (Barile
et al., 2014, 2018), optimizing test parameters (cell type, culture
conditions, timing), and using a different and more quantitative
detection method (fluorescence detection by plate reader instead
of fluorescence microscopy followed by image analysis). The
optimized test resulted more reproducible and suitable for formal
GMP validation.
GMP-Exo-CPC were frozen at −80◦C in single-dose aliquots,
as convenient for a ready-to-use therapeutic product (Witwer
et al., 2013). A stability study is ongoing; partial results obtained
so far indicate no loss of functional activity in the storage
conditions after 7 months.
A preclinical study in swine myocardial infarction model
is now ongoing, to further test the safety and efficacy of the
product.
The production of GMP-Exo-CPC lots to be used for
first-in-man study will be carried out, starting from the MCB
produced for clinical use, in a GMP certified and classified area.
Each lot will be analyzed according to an extended QC panel in
order to be released for clinical application.
CONCLUSION
The large-scale process described here, based on an innovative
approach combining several steps in an integrated circuit, led
to a safe and well characterized GMP-Exo-CPC product. This
manufacturing method may be also applied to Exo from other cell
sources (e.g., mesenchymal stem cells, muscle cells, fibroblasts,
nervous system cells, dendritic cells, etc.), for different clinical
applications.
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